Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

MIRA reports positive results supporting MIRA-55 as non-opioid oral pain therapy

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the company’s oral drug candidate being developed as a non-opioid...

July 10, 2026

Developments

Analysis shows 22% cut in NICU admissions in first-time pregnancies with Sera’s PreTRM

Sera Prognostics (NASDAQ: SERA) has announced publication of a new subgroup analysis from the PRIME trial demonstrating that its PreTRM Test-guided care in first-time pregnancies significantly improved neonatal...

July 10, 2026

Developments

Rani and PegBio join forces to expand obesity pipeline

Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic...

July 10, 2026

Developments

Evogene and BCDD collaborate in drug discovery initiative

Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating...

July 9, 2026

Developments

CervoMed completes enrollment for study of neflamapimod in nfvPPA

CervoMed (NASDAQ: CRVO) has announced that it has completed enrollment in the Phase 2a study to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in patients with nonfluent/agrammatic variant...

July 9, 2026

Developments

First patient dosed in Delcath’s global trial of HEPZATO in mBC

Delcath Systems (NASDAQ: DCTH) has announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy, in its global Phase 2 clinical trial evaluating HEPZATO in combination with...

July 9, 2026

Developments

MAIA reports strong data from trial of 3L therapy in NSCLC

MAIA Biotechnology (NYSE American: MAIA) has announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action...

July 9, 2026

Developments

FDA grants RPDD to Vanda’s investigational CMT2S therapy

Vanda Pharmaceuticals (NASDAQ: VNDA) has announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its investigational antisense oligonucleotide therapy—VCA-894A—for the treatment of Charcot-Marie...

July 8, 2026

Markets

WB starts Zura Bio at OP; sum-of-the-parts NPV estimate $13.90

William Blair launched coverage of Zura Bio (NASDAQ:ZURA) with an “outperform” rating and sum-of-the-parts NPV estimate of $13.90. The stock closed at $5.08 on July 7. Zura is a clinical-stage, multi-asset immunology...

July 8, 2026

Executive Moves

Laurie Keating joins Kalaris BOD

Kalaris Therapeutics (NASDAQ: KLRS) has announced the appointment of Laurie Keating to its board of directors (BOD), effective August 1, 2026, and the departure of Morana Jovan-Embiricos from the board. Ms. Keating...

July 7, 2026

Executive Moves

Longeveron appoints Marie Washburn as CFO

Longeveron (NASDAQ: LGVN) has announced the appointment of Marie Washburn as senior vice president and chief financial officer (CFO), effective July 13, 2026. Ms. Washburn has served as Longeveron’s vice president...

July 7, 2026

Developments

FDA accepts Organogenesis’ ReNu BLA for knee OA

Organogenesis Holdings (NASDAQ: ORGO) has announced that the FDA has accepted for review its Biologics License Application (BLA) for ReNu, a cryopreserved, amniotic suspension allograft developed for the treatment of...

July 7, 2026

Subscribe